Core Viewpoint - argenx is actively engaging in the healthcare sector by participating in conferences to discuss advancements in immunology and its commitment to treating severe autoimmune diseases [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, exploring its potential across multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]. Event Participation - Karen Massey, the Chief Operating Officer of argenx, will participate in a fireside chat at the TD Cowen 46 Annual Healthcare Conference on March 2 at 11:50 a.m. ET [1]. - A live webcast of the presentation will be available on the Investors section of the argenx website, with a replay accessible for approximately 30 days following the event [2].

Core Points - argenx SE, a global immunology company, held its Extraordinary General Meeting of shareholders on November 18, 2025, to discuss its remuneration policy [1] - The remuneration policy was approved with a significant majority of 95.67%, with 91.1% of share capital represented at the meeting [2] Company Overview - argenx is dedicated to improving the lives of individuals suffering from severe autoimmune diseases and collaborates with leading academic researchers through its Immunology Innovation Program [3] - The company has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential across various serious autoimmune diseases while advancing several earlier-stage experimental medicines [3]

Core Insights - argenx will host a conference call and audio webcast on October 30, 2025, at 1:30 PM CET to discuss its Q3 2025 financial results and provide a business update [1]. Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3]. - The company collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to translate immunology breakthroughs into a portfolio of novel antibody-based medicines [3]. - argenx has developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, evaluating its potential in multiple serious autoimmune diseases while advancing several earlier-stage experimental medicines [3].

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations for its potential in various serious autoimmune diseases [3] Upcoming Events - argenx will host a conference call and audio webcast on May 8, 2025, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update [1] - A live webcast of the call will be accessible on the Investors section of the argenx website, with a replay available for approximately one year [2] Contact Information - Media inquiries can be directed to Ben Petok via email at bpetok@argenx.com [4] - Investor relations can be contacted through Alexandra Roy at aroy@argenx.com [4]